Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema for painful diabetic peripheral neuropathy in type 2 diabetes
2023-509662-38-00Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2024
- Modality
- Peptides
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and diabetic polyneuropathy (DPN) comparing CagriSema once weekly with Placebo once weekly (2 arms). Primary endpoint: Change in weekly average Pain Intensity-Numerical Rating Scale (PI-NRS). Started Dec 2024; status: completed.
02
Drugs
CagriSema
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on 2023-509662-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509662-38-00.